The benefits of statin therapy--what questions remain?

摘要: Early hydroxymethylglutaryl-CoA reductase inhibitor (statin) trials provided the first evidence of benefits statin therapy in secondary prevention coronary heart disease (CHD). Outcomes data from more recent involving atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin, have since expanded patient population shown to benefit therapy. Current studies are evaluating lowering lipid levels with statins below current goals, as well examining special populations value surrogate markers CHD. a solid foundation knowledge on efficacy safety statins. Recent ongoing generate new resolve remaining questions fields CHD lipidology.